BNP Paribas Financial Markets’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,962
| Closed | -$4K | – | 4325 |
|
|
2021
Q3 | $4K | Sell |
1,962
-549
| -22% | -$1.28K | ﹤0.01% | 3726 |
|
|
2021
Q2 | $7.46K | Sell |
2,511
-3,932
| -61% | -$10.4K | ﹤0.01% | 3773 |
|
|
2021
Q1 | $17.8K | Sell |
6,443
-3,240
| -33% | -$9.78K | ﹤0.01% | 3776 |
|
|
2020
Q4 | $23.5K | Buy |
9,683
+531
| +6% | +$1.28K | ﹤0.01% | 3812 |
|
|
2020
Q3 | $19.2K | Buy |
9,152
+7,335
| +404% | +$24.7K | ﹤0.01% | 3844 |
|
|
2020
Q2 | $6.87K | Sell |
1,817
-9,321
| -84% | -$27.9K | ﹤0.01% | 3875 |
|
|
2020
Q1 | $21.1K | Buy |
11,138
+2,500
| +29% | +$6.5K | ﹤0.01% | 3898 |
|
|
2019
Q4 | $18.1K | Buy |
8,638
+6,978
| +420% | +$13.4K | ﹤0.01% | 4029 |
|
|
2019
Q3 | $3.97K | Buy |
+1,660
| New | +$4.46K | ﹤0.01% | 4300 |
|
|
2019
Q2 | – | Sell |
-31
| Closed | -$154 | – | 4611 |
|
|
2019
Q1 | $154 | Hold |
31
| – | – | ﹤0.01% | 4212 |
|
|
2018
Q4 | $139 | Buy |
+31
| New | +$151 | ﹤0.01% | 4146 |
|
|
2018
Q2 | – | Sell |
-5,472
| Closed | -$48.4K | – | 4507 |
|
|
2018
Q1 | $48.4K | Sell |
5,472
-446
| -8% | -$3.34K | ﹤0.01% | 3581 |
|
|
2017
Q4 | $42.9K | Buy |
5,918
+3,779
| +177% | +$23.6K | ﹤0.01% | 3748 |
|
|
2017
Q3 | $14.8K | Sell |
2,139
-158
| -7% | -$1.09K | ﹤0.01% | 3749 |
|
|
2017
Q2 | $16.4K | Buy |
+2,297
| New | +$10.6K | ﹤0.01% | 3768 |
|
BNP Paribas Financial Markets's SBBP Position: Q4 2021 in Review
BNP Paribas Financial Markets sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 1,962 shares — an estimated $4K sold.
BNP Paribas Financial Markets first reported a position in SBBP in Q2 2017 and held it in 15 quarters. The position peaked at $48.4K in Q1 2018. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- BNP Paribas Financial Markets reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- BNP Paribas Financial Markets sold 1,962 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $4K.
- BNP Paribas Financial Markets first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 15 quarters.
- BNP Paribas Financial Markets's Strongbridge Biopharma plc. position peaked at $48.4K in Q1 2018.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2021, filed 9 Feb 2022.